Loxo Oncology (LOXO) Getting Somewhat Favorable News Coverage, Study Shows

Media headlines about Loxo Oncology (NASDAQ:LOXO) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Loxo Oncology earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.739073636374 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

LOXO has been the subject of several recent analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $91.00 price objective on shares of Loxo Oncology in a research note on Monday, June 19th. Ifs Securities restated an “outperform” rating on shares of Loxo Oncology in a research report on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and set a $71.00 target price on shares of Loxo Oncology in a research report on Thursday, August 3rd. Zacks Investment Research upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 target price for the company in a research report on Wednesday, August 9th. Finally, JMP Securities cut shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $83.12 to $17.14 in a research report on Tuesday, August 29th. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Loxo Oncology has a consensus rating of “Buy” and an average price target of $76.31.

Loxo Oncology (LOXO) opened at 92.26 on Wednesday. The firm’s market cap is $2.75 billion. The firm’s 50-day moving average is $84.09 and its 200-day moving average is $66.92. Loxo Oncology has a 12 month low of $17.14 and a 12 month high of $95.92.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). During the same quarter in the prior year, the business earned ($0.77) EPS. Equities analysts expect that Loxo Oncology will post ($4.49) earnings per share for the current year.

In other Loxo Oncology news, VP Jennifer Burstein sold 1,700 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $73.73, for a total transaction of $125,341.00. Following the completion of the sale, the vice president now directly owns 1,700 shares of the company’s stock, valued at $125,341. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Avi Z. Naider sold 5,000 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $90.00, for a total transaction of $450,000.00. Following the sale, the director now directly owns 154,118 shares of the company’s stock, valued at $13,870,620. The disclosure for this sale can be found here. Insiders sold a total of 84,896 shares of company stock valued at $6,865,562 over the last three months. 27.80% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING:

LOXO has been the subject of several recent analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $91.00 price objective on shares of Loxo Oncology in a research note on Monday, June 19th. Ifs Securities restated an “outperform” rating on shares of Loxo Oncology in a research report on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and set a $71.00 target price on shares of Loxo Oncology in a research report on Thursday, August 3rd. Zacks Investment Research upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 target price for the company in a research report on Wednesday, August 9th. Finally, JMP Securities cut shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $83.12 to $17.14 in a research report on Tuesday, August 29th. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Loxo Oncology has a consensus rating of “Buy” and an average price target of $76.31.

Loxo Oncology (LOXO) opened at 92.26 on Wednesday. The firm’s market cap is $2.75 billion. The firm’s 50-day moving average is $84.09 and its 200-day moving average is $66.92. Loxo Oncology has a 12 month low of $17.14 and a 12 month high of $95.92.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). During the same quarter in the prior year, the business earned ($0.77) EPS. Equities analysts expect that Loxo Oncology will post ($4.49) earnings per share for the current year.

In other Loxo Oncology news, VP Jennifer Burstein sold 1,700 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $73.73, for a total transaction of $125,341.00. Following the completion of the sale, the vice president now directly owns 1,700 shares of the company’s stock, valued at $125,341. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Avi Z. Naider sold 5,000 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $90.00, for a total transaction of $450,000.00. Following the sale, the director now directly owns 154,118 shares of the company’s stock, valued at $13,870,620. The disclosure for this sale can be found here. Insiders sold a total of 84,896 shares of company stock valued at $6,865,562 over the last three months. 27.80% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This news story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/11/loxo-oncology-loxo-getting-somewhat-favorable-news-coverage-study-shows.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply